AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ephrin-A1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P20827

UPID:

EFNA1_HUMAN

Alternative names:

EPH-related receptor tyrosine kinase ligand 1; Immediate early response protein B61; Tumor necrosis factor alpha-induced protein 4

Alternative UPACC:

P20827; D3DV86; Q5SR60; Q5SR61; Q6I9T9; Q8N578

Background:

Ephrin-A1, known as EPH-related receptor tyrosine kinase ligand 1, plays a pivotal role in neuronal, vascular, and epithelial development through its interaction with Eph receptors. It facilitates crucial processes such as migration, repulsion, and adhesion by engaging in bidirectional signaling. Moreover, Ephrin-A1 is instrumental in angiogenesis and tumor neovascularization, influencing cell migration and assembly via RAC1 GTPase activation.

Therapeutic significance:

Understanding the role of Ephrin-A1 could open doors to potential therapeutic strategies. Its ability to activate and down-regulate EPHA2 presents anti-oncogenic effects in tumor cells, highlighting its significance in cancer research. Additionally, its negative regulatory role in glioma tumorigenesis underscores its potential as a therapeutic target.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.